As part of our ongoing aim to bring you reports of significant developments, we have added a review of the phase 3 VIALE-A trial. This evaluated the efficacy and safety of venetoclax plus azacitidine vs a control regimen of placebo plus azacitidine in previously untreated patients with acute myeloid leukaemia.
Independent commentary is provided by Dr Chun Yew Fong, a clinical haematologist and senior staff specialist at Austin Hospital and the Head of Acute Leukaemia and Myelodysplastic Syndromes.
Please login below to download this issue (PDF)